nach oben

International Urology and Nephrology

Erschienen in:

10.12.2016 | Nephrology - Original Paper

The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients

Erschienen in: International Urology and Nephrology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Finding new, reliable biomarkers of cardiovascular risk in hemodialysis (HD) patients is of utmost importance. Fibroblast growth factor 21 (FGF21) has been recently associated with atherosclerosis in the general population. The relationship between markedly elevated FGF21 levels in HD patients and endothelial dysfunction is unknown. The aim of the study was to assess the determinants of FGF21, the correlation between FGF21 and tumor necrosis factor TNF-like weak inducer of apoptosis (sTWEAK) and the correlation between FGF21 and endothelial dysfunction in HD patients.

Methods

A cross-sectional observational study was conducted in 70 HD patients (mean age 59.9 ± 12.5 years, 14.3% diabetes mellitus, 57.1% male) from Nefromed Dialysis Center Cluj. We registered clinical and biological data, and serum FGF21 levels were measured by ELISA. Endothelial function was evaluated by brachial flow-mediated dilation (FMD). An analysis based on stratification of FGF21 values into quartiles was performed.

Results

FGF21 levels were directly correlated with sTWEAK, tricipital skinfold thickness (TST), systolic blood pressure (SBP), total cholesterol and triglycerides. In multivariate linear analysis, only sTWEAK and SBP remained significantly associated with FGF21. FGF21 values in the inferior quartile were directly correlated with HDL-cholesterol, while FGF21 values in the superior quartile were directly correlated with SBP, pulse pressure and sTWEAK. FMD was significantly higher in the inferior quartile as compared to the superior quartile.

Conclusions

High FGF21 values in our patients are correlated with atherosclerosis risk factors: hypercholesterolemia, hypertriglyceridemia, hypertension, increased TST and increased levels of sTWEAK. Endothelial dysfunction is associated with high FGF21 in HD patients.

Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235–253CrossRefPubMedPubMedCentral

Kralisch S, Tönjes A, Krause K, Richter J, Lossner U, Kovacs P, Ebert T, Blüher M, Stumvoll M, Fasshauer M (2013) Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol 216:135–143CrossRefPubMed

Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774–781CrossRefPubMed

Li K, Li L, Yang M, Liu H, Boden G, Yang G (2012) The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol 348:21–26CrossRefPubMed

Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027CrossRefPubMed

Hermansen K, Davies M (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9:209–217CrossRefPubMed

Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RLC, Chow WS, Tso AWK, Lam KSL, Xu A (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246–1253CrossRefPubMed

Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, Feng W, Li X (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 6:e18398. doi:10.1371/journal.pone.001839 CrossRefPubMedPubMedCentral

Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, Wong MC, Turner C, Palmer CNA, Nogoceke E, Groop L, Salomaa V, Dunger DB, Agakov F, McKeigue PM, Colhoun HM, Investigators SUMMIT (2015) Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int 88:888–896CrossRefPubMed

10.

Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS, Kim YB, Jang HC, Park KS (2010) Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59:1656–1662CrossRefPubMed

11.

Xiao Y, Liu L, Xu A, Zhou P, Long Z, Tu Y, Chen X, Tang W, Huang G, Zhou Z (2015) Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 6:14–72

12.

Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, Tse HF, Chau MT, Cheung BM, Lam KS (2013) Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 33:2454–2459CrossRefPubMed

13.

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 28:12–124

14.

Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 5:e15534. doi:10.1371/journal.pone.0015534 CrossRefPubMedPubMedCentral

15.

Zhang W, Chu S, Ding W, Wang F (2015) Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS ONE 10:e0129791. doi:10.1371/journal.pone.0129791 CrossRefPubMedPubMedCentral

16.

Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L (2013) Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens 27:397–399CrossRefPubMed

17.

Hindricks J, Ebert T, Bachmann A, Kralisch S, Lössner U, Kratzsch J, Stolzenburg JU, Dietel A, Beige J, Anders M, Bast I, Blüher M, Stumvoll M, Fasshauer M (2014) Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol 80:918–924CrossRef

18.

Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32:126–128CrossRefPubMedPubMedCentral

19.

Ulu SM, Yuksel S, Altuntaş A, Kacar E, Ahsen A, Altug A, Celik S, Sezer MT (2014) Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol 46:2409–2414CrossRefPubMed

20.

Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ (2011) Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 6:785–792CrossRefPubMedPubMedCentral

21.

Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115CrossRefPubMed

22.

Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M, Di Monaco A, De Siati L, Volpe M, Ambrosio G, Gemignani V, Muiesan ML, Taddei S, Lanza GA, Cosentino F (2012) Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens 30:1399–1405CrossRefPubMed

23.

Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151–2156CrossRefPubMed

24.

Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T (2008) βKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22:1006–1014CrossRefPubMed

25.

Iglesias P, Selgas R, Romero S, Díez JJ (2012) Biological role, clinical significance and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167:301–309CrossRefPubMed

26.

Eto K (2013) FGF-21, a newcomer in the field of hypertension research. J Hum Hypertens 27:343–344CrossRefPubMed

27.

Tomiyama K, Maeda R, Urakawa I, Yamazaki Y, Tanaka T, Ito S, Nabeshima Y, Tomita T, Odori S, Hosoda K, Nakao K, Imura A, Nabeshima Y (2010) Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A 107:1666–1671CrossRefPubMedPubMedCentral

28.

Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SY, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA (1999) The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274:33166–33176CrossRefPubMed

29.

Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207:103–110CrossRefPubMed

30.

Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG (2015) The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients. Int Urol Nephrol 47:2023–2030CrossRefPubMed

31.

Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A (2014) TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant 29(Suppl 1):i54–i62CrossRefPubMedPubMedCentral

32.

Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB (2011) The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 22:1315–1325CrossRefPubMedPubMedCentral

33.

Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH (2004) TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68:396–399CrossRefPubMed

34.

Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F (2012) TNF-alpha represses beta-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153:4238–4245CrossRefPubMed

35.

Jin QR, Bando Y, Miyawaki K, Shikama Y, Kosugi C, Aki N, Funaki M, Noji S (2014) Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Investig 61:28–34CrossRef

36.

Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA (2012) Fibroblast growth factor-21 regulates PPAR gamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556–567CrossRefPubMedPubMedCentral

37.

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M (2007) Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687–26695CrossRefPubMedPubMedCentral

Titel: The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients
Publikationsdatum: 10.12.2016
Erschienen in: International Urology and Nephrology / Ausgabe 3/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1474-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis

Obesity, acute kidney injury and outcome of critical illness

Measuring creatinine excretion and clearance for diagnosing and staging chronic kidney disease

Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative

Community-acquired hypokalemia in elderly patients: related factors and clinical outcomes